Filing Details

Accession Number:
0001209191-17-041062
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-20 16:07:09
Reporting Period:
2017-06-17
Filing Date:
2017-06-20
Accepted Time:
2017-06-20 16:07:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
816284 Celgene Corp CELG Pharmaceutical Preparations (2834) 222711928
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1190435 D Michael Casey C/O Celgene Corporation
86 Morris Avenue
Summit NJ 07901
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-06-17 333 $0.00 0 No 4 M Direct
Common Stock Acquisiton 2017-06-19 9,250 $125.59 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2017-06-17 333 $0.00 333 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
334 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 92,070 Indirect Family Trust
Footnotes
  1. One-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock.
  2. The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $125.57 to $125.60, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  3. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  4. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
  5. The balance of the restricted stock units will vest on June 17, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date.
  6. The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated on April 15, 2015)).